Deciphera Pharmaceuticals Inc

Deciphera Pharmaceuticals Inc is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for cancer treatment. The company's proprietary platform technology allows for the identification of novel kinase inhibitors that selectively target cancer cells while sparing healthy cells. Ripretinib, Deciphera's lead product candidate, is a kinase inhibitor being developed for the treatment of gastrointestinal stromal tumors (GIST) and other solid tumors. The company is also developing a pipeline of other kinase inhibitors for various cancer treatments. Deciphera is committed to advancing its innovative therapies through clinical development and regulatory approval to improve the lives of cancer patients.